University of Wolverhampton
Browse
Collection All
bullet
bullet
bullet
bullet
Listed communities
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

Wolverhampton Intellectual Repository and E-Theses > Research Institutes > Research Institute in Healthcare Science > Cancer Research Group > Regulation of uncoupling protein-2 (UCP-2) expression in human glioma cells by peroxisome proliferators-activated receptor (PPAR) agonists

Please use this identifier to cite or link to this item: http://hdl.handle.net/2436/29933
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!



Title: Regulation of uncoupling protein-2 (UCP-2) expression in human glioma cells by peroxisome proliferators-activated receptor (PPAR) agonists
Other Titles: In: Abstracts from the World Federation of Neuro-Oncology 2nd Quadrennial Meeting and the 6th Meeting of the European Association for Neuro-Oncology, May 5–8, 2005, Edinburgh, UK. No.56
Authors: Brown, James E. P.
Darling, John L.
Dunmore, Simon J.
Bassey, S.
Citation: Neuro-oncology, 7(3): 296
Publisher: Society for Neuro-Oncology and Duke University Press
Journal: Neuro-oncology
Issue Date: 2005
URI: http://hdl.handle.net/2436/29933
Additional Links: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1871910
Abstract: Recent studies have suggested that the glitazones, a group of PPAR agonists commonly prescribed as therapy in type 2 diabetes, could have a role in regulation of cell viability in astrocytomas and glioma cell lines, possibly due to a modulation of reactive oxygen species (ROS) production. PPAR agonists are also known to regulate expression of the mitochondrial protein UCP-2, and UCP-2 has a purported role in ROS regulation amongst others. This study investigated the expression of UCP-2 in U251MG glioma cells and its regulation by PPAR agonists. U251MG glioma cells were cultured according to standard methods and treated with PPAR alpha, delta, and gamma agonists (10 μM WY14643, 10 nM PGI2, 10 μM rosiglitazone and 10 nM PGJ2, respectively) for 24 h. Total RNA was subsequently extracted and semiquantitative RT-PCR used to evaluate UCP-2 mRNA expression. Results showed that UCP-2 was expressed in all control and treatment samples and that its expression was regulated differentially by the various PPAR receptor subtype agonists tested. This novel finding that UCP-2 is expressed in glioma cells, and that its expression is regulated by PPAR agonists, suggests a potential mechanism for the cytotoxic effects of glitazones that have been previously reported, and describes a mechanism which could possibly be manipulated as a potential therapeutic avenue in the future.
Type: Meetings & Proceedings
Language: en
Description: Abstracts from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Duke University Press
Keywords: Cancer genetics
Brain Tumours
Chemotherapeutic targets
Malignant Tumours
Glioma
U251MG
RNA
PPAR agonists
UCP-2
Astrogliomas
Reactive Oxygen Species
Glitazones
Astrocytoma
Oncology
MeSH: Cell Line, Tumor
ISSN: 1522-8517
Appears in Collections: Cancer Research Group

Files in This Item:

There are no files associated with this item.



All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Fairtrade - Guarantees a better deal for Third World Producers

University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1LY

Course enquiries: 0800 953 3222, General enquiries: 01902 321000,
Email: enquiries@wlv.ac.uk | Freedom of Information | Disclaimer and copyright | Website feedback | The University as a charity

OR Logo Powered by Open Repository | Cookies